|
1
|
Ding Y, Xing D, Fei Y and Lu B: Emerging
degrader technologies engaging lysosomal pathways. Chem Soc Rev.
51:8832–8876. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang TY, Shi YY, Cui XW, Pan YF, Lin YK,
Feng XF, Ding ZW, Yang C, Tan YX, Dong LW and Wang HY: PTEN
deficiency facilitates exosome secretion and metastasis in
cholangiocarcinoma by impairing TFEB-mediated lysosome biogenesis.
Gastroenterology. 164:424–438. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karbowski M, Oshima Y and Verhoeven N:
Mitochondrial proteotoxicity: implications and ubiquitin-dependent
quality control mechanisms. Cell Mol Life Sci. 79:5742022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sinam IS, Chanda D, Thoudam T, Kim MJ, Kim
BG, Kang HJ, Lee JY, Baek SH, Kim SY, Shim BJ, et al: Pyruvate
dehydrogenase kinase 4 promotes ubiquitin-proteasome
system-dependent muscle atrophy. J Cachexia Sarcopenia Muscle.
13:3122–3136. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Brien S, Kelso S, Steinhart Z, Orlicky
S, Mis M, Kim Y, Lin S, Sicheri F and Angers S: SCF
FBXW7 regulates G2-M progression through control of
CCNL1 ubiquitination. EMBO Rep. 23:e550442022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Capecchi MR and Pozner A: ASPM regulates
symmetric stem cell division by tuning Cyclin E ubiquitination. Nat
Commun. 6:87632015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J
and Xu Z: Cytosolic TGM2 promotes malignant progression in gastric
cancer by suppressing the TRIM21-mediated
ubiquitination/degradation of STAT1 in a GTP binding-dependent
modality. Cancer Commun (Lond). 43:123–149. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng X, Jia Y, Zhang Y, Ma F, Zhu Y, Hong
X, Zhou Q, He R, Zhang H, Jin J, et al: Ubiquitination of UVRAG by
SMURF1 promotes autophagosome maturation and inhibits
hepatocellular carcinoma growth. Autophagy. 15:1130–1149. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H, Wang N, Jiang Y, Wang H, Xin Z, An
H, Pan H, Ma W, Zhang T, Wang X and Lin W: E3 ubiquitin ligase
NEDD4L negatively regulates inflammation by promoting
ubiquitination of MEKK2. EMBO Rep. 23:e546032022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nan Y, Luo Q, Wu X, Chang W, Zhao P, Liu S
and Liu Z: HCP5 prevents ubiquitination-mediated UTP3 degradation
to inhibit apoptosis by activating c-Myc transcriptional activity.
Mol Ther. 31:552–568. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao HJ, Jiang H, Ding K, Qiu XS, Ma N,
Zhang FK, Wang YK, Zheng QW, Xia J, Ni QZ, et al: ARID2 mitigates
hepatic steatosis via promoting the ubiquitination of JAK2. Cell
Death Differ. 30:383–396. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mattiroli F and Penengo L: Histone
ubiquitination: An integrative signaling platform in genome
stability. Trends Genet. 37:566–581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roberts JZ, Crawford N and Longley DB: The
role of ubiquitination in apoptosis and necroptosis. Cell Death
Differ. 29:272–284. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang K, Liu J, Li YL, Li JP and Zhang R:
Ubiquitination/de-ubiquitination: A promising therapeutic target
for PTEN reactivation in cancer. Biochim Biophys Acta Rev Cancer.
1877:1887232022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Wei L, Hu N, Wang D, Ni J, Zhang S,
Liu H, Lv T, Yin J, Ye M and Song Y: FBW7-mediated ubiquitination
and destruction of PD-1 protein primes sensitivity to anti-PD-1
immunotherapy in non-small cell lung cancer. J Immunother Cancer.
10:e0051162022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Wang T, She Y, Wu K, Gu S, Li L,
Dong C, Chen C and Zhou Y: N6-methyladenosine-modified
circIGF2BP3 inhibits CD8+ T-cell responses to facilitate
tumor immune evasion by promoting the deubiquitination of PD-L1 in
non-small cell lung cancer. Mol Cancer. 20:1052021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu L, Zhao N, Zhou Z, Chen J, Han S, Zhang
X, Bao H, Yuan W and Shu X: PLAGL2 promotes the proliferation and
migration of gastric cancer cells via USP37-mediated
deubiquitination of Snail1. Theranostics. 11:700–714. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie H, Zhou J, Liu X, Xu Y, Hepperla AJ,
Simon JM, Wang T, Yao H, Liao C, Baldwin AS, et al: USP13 promotes
deubiquitination of ZHX2 and tumorigenesis in kidney cancer. Proc
Natl Acad Sci USA. 119:e21198541192022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rasaei R, Sarodaya N, Kim KS, Ramakrishna
S and Hong SH: Importance of deubiquitination in
macrophage-mediated viral response and inflammation. Int J Mol Sci.
21:80902020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun T, Liu Z and Yang Q: The role of
ubiquitination and deubiquitination in cancer metabolism. Mol
Cancer. 19:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai J, Culley MK, Zhao Y and Zhao J: The
role of ubiquitination and deubiquitination in the regulation of
cell junctions. Protein Cell. 9:754–769. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou Y, Park SH and Chua NH:
UBP12/UBP13-mediated deubiquitination of salicylic acid receptor
NPR3 suppresses plant immunity. Mol Plant. 16:232–244. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen S, Liu Y and Zhou H: Advances in the
development ubiquitin-specific peptidase (USP) inhibitors. Int J
Mol Sci. 22:45462021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato Y, Goto E, Shibata Y, Kubota Y,
Yamagata A, Goto-Ito S, Kubota K, Inoue J, Takekawa M, Tokunaga F
and Fukai S: Structures of CYLD USP with Met1- or Lys63-linked
diubiquitin reveal mechanisms for dual specificity. Nat Struct Mol
Biol. 22:222–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maertens GN, El Messaoudi-Aubert S,
Elderkin S, Hiom K and Peters G: Ubiquitin-specific proteases 7 and
11 modulate Polycomb regulation of the INK4a tumour suppressor.
EMBO J. 29:2553–2565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cruz L, Soares P and Correia M:
Ubiquitin-Specific proteases: Players in cancer cellular processes.
Pharmaceuticals (Basel). 14:8482021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mansilla A, Martin FA, Martin D and Ferrus
A: Ligand-independent requirements of steroid receptors EcR and USP
for cell survival. Cell Death Differ. 23:405–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
An Z, Liu Y, Ou Y, Li J, Zhang B, Sun D,
Sun Y and Tang W: Regulation of the stability of RGF1 receptor by
the ubiquitin-specific proteases UBP12/UBP13 is critical for root
meristem maintenance. Proc Natl Acad Sci USA. 115:1123–1128. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lim JH, Jono H, Komatsu K, Woo CH, Lee J,
Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively
regulates transforming growth factor-β-signalling via
deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bonacci T and Emanuele MJ: Dissenting
degradation: Deubiquitinases in cell cycle and cancer. Semin Cancer
Biol. 67((Pt 2)): 145–158. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Xia S, Li H, Wang X, Li C, Chao Y,
Zhang L and Han C: The deubiquitinase USP10 regulates KLF4
stability and suppresses lung tumorigenesis. Cell Death Differ.
27:1747–1764. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baek SH, Choi KS, Yoo YJ, Cho JM, Baker
RT, Tanaka K and Chung CH: Molecular cloning of a novel
ubiquitin-specific protease, UBP41, with isopeptidase activity in
chick skeletal muscle. J Biol Chem. 272:25560–25565. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gousseva N and Baker RT: Gene structure,
alternate splicing, tissue distribution, cellular localization, and
developmental expression pattern of mouse deubiquitinating enzyme
isoforms Usp2-45 and Usp2-69. Gene Expr. 11:163–179. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moremen KW, Touster O and Robbins PW:
Novel purification of the catalytic domain of Golgi
alpha-mannosidase II. Characterization and comparison with the
intact enzyme. J Biol Chem. 266:16876–16885. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gerhard DS, Wagner L, Feingold EA, Shenmen
CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, et
al: The status, quality, and expansion of the NIH full-length cDNA
project: The Mammalian Gene Collection (MGC). Genome Res.
14((10B)): 2121–2127. 2004.PubMed/NCBI
|
|
36
|
Ota T, Suzuki Y, Nishikawa T, Otsuki T,
Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, et al:
Complete sequencing and characterization of 21,243 full-length
human cDNAs. Nat Genet. 36:40–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luo H, Ji Y, Gao X, Liu X and Wu Y and Wu
Y: Ubiquitin specific protease 2: Structure, isoforms, cellular
function, relateddiseases and its inhibitors. Oncologie. 24:85–99.
2022. View Article : Google Scholar
|
|
38
|
Zhu HQ and Gao FH: The molecular
mechanisms of regulation on USP2′s alternative splicing and the
significance of its products. Int J Biol Sci. 13:1489–1496. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pouly D, Chenaux S, Martin V, Babis M,
Koch R, Nagoshi E, Katanaev VL, Gachon F and Staub O: USP2-45 is a
circadian clock output effector regulating calcium absorption at
the post-translational level. PLoS One. 11:e01451552016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tong X, Buelow K, Guha A, Rausch R and Yin
L: USP2a protein deubiquitinates and stabilizes the circadian
protein CRY1 in response to inflammatory signals. J Biol Chem.
287:25280–25291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Molusky MM, Li S, Ma D, Yu L and Lin JD:
Ubiquitin-specific protease 2 regulates hepatic gluconeogenesis and
diurnal glucose metabolism through 11β-hydroxysteroid dehydrogenase
1. Diabetes. 61:1025–1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kitamura H, Kimura S, Shimamoto Y, Okabe
J, Ito M, Miyamoto T, Naoe Y, Kikuguchi C, Meek B, Toda C, et al:
Ubiquitin-specific protease 2–69 in macrophages potentially
modulates metainflammation. FASEB J. 27:4940–4953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang S, Wu H, Liu Y, Sun J, Zhao Z, Chen
Q, Guo M, Ma D and Zhang Z: Expression of USP2-69 in mesangial
cells in vivo and in vitro. Pathol Int. 60:184–192. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haimerl F, Erhardt A, Sass G and Tiegs G:
Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific
protease 2 contributes to tumor necrosis factor-alpha-induced
hepatocyte survival. J Biol Chem. 284:495–504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Kim BG, Qian S, Letterio JJ, Fung
JJ, Lu L and Lin F: Hepatic stellate cells inhibit T cells through
active TGF-β1 from a cell surface-bound latent TGF-β1/GARP complex.
J Immunol. 195:2648–2656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mao X, Luo W, Sun J, Yang N, Zhang LW,
Zhao Z, Zhang Z and Wu H: Usp2-69 overexpression slows down the
progression of rat anti-Thy1.1 nephritis. Exp Mol Pathol.
101:249–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kitamura H, Ishino T, Shimamoto Y, Okabe
J, Miyamoto T, Takahashi E and Miyoshi I: Ubiquitin-Specific
protease 2 modulates the lipopolysaccharide-elicited expression of
proinflammatory cytokines in macrophage-like HL-60 cells. Mediators
Inflamm. 2017:69094152017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mahul-Mellier AL, Datler C, Pazarentzos E,
Lin B, Chaisaklert W, Abuali G and Grimm S: De-ubiquitinating
proteases USP2a and USP2c cause apoptosis by stabilising RIP1.
Biochim Biophys Acta. 1823:1353–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Davis MI, Pragani R, Fox JT, Shen M,
Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD, et al:
Small molecule inhibition of the ubiquitin-specific protease USP2
Accelerates cyclin D1 degradation and leads to cell cycle arrest in
colorectal cancer and mantle cell lymphoma models. J Biol Chem.
291:24628–24640. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bedard N, Yang Y, Gregory M, Cyr DG,
Suzuki J, Yu X, Chian RC, Hermo L, O'Flaherty C, Smith CE, et al:
Mice lacking the USP2 deubiquitinating enzyme have severe male
subfertility associated with defects in fertilization and sperm
motility. Biol Reprod. 85:594–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu Q, Liu M, Zhang F, Liu X, Ling S, Chen
X, Gu J, Ou W, Liu S and Liu N: Ubiquitin-specific protease 2
regulates Ang II-induced cardiac fibroblasts activation by
up-regulating cyclin D1 and stabilizing β-catenin in vitro. J Cell
Mol Med. 25:1001–1011. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hashimoto M, Fujimoto M, Konno K, Lee ML,
Yamada Y, Yamashita K, Toda C, Tomura M, Watanabe M, Inanami O and
Kitamura H: Ubiquitin-Specific protease 2 in the ventromedial
hypothalamus modifies blood glucose levels by controlling
sympathetic nervous activation. J Neurosci. 42:4607–4618. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu XQ, Shao XR, Liu Y, Dong ZX, Chan SH,
Shi YY, Chen SN, Qi L, Zhong L, Yu Y, et al: Tight junction protein
1 promotes vasculature remodeling via regulating USP2/TWIST1 in
bladder cancer. Oncogene. 41:502–514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tu Y, Xu L, Xu J, Bao Z, Tian W, Ye Y, Sun
G, Miao Z, Chao H, You Y, et al: Loss of deubiquitylase USP2
triggers development of glioblastoma via TGF-β signaling. Oncogene.
41:2597–2608. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nadolny C, Zhang X, Chen Q, Hashmi SF, Ali
W, Hemme C, Ahsan N, Chen Y and Deng R: Dysregulation and
activities of ubiquitin specific peptidase 2b in the pathogenesis
of hepatocellular carcinoma. Am J Cancer Res. 11:4746–4767.
2021.PubMed/NCBI
|
|
56
|
Zhang J, Liu S, Li Q, Shi Y, Wu Y, Liu F,
Wang S, Zaky MY, Yousuf W, Sun Q, et al: The deubiquitylase USP2
maintains ErbB2 abundance via counteracting endocytic degradation
and represents a therapeutic target in ErbB2-positive breast
cancer. Cell Death Differ. 27:2710–2725. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qu Q, Mao Y, Xiao G, Fei X, Wang J, Zhang
Y, Liu J, Cheng G, Chen X, Wang J and Shen K: USP2 promotes cell
migration and invasion in triple negative breast cancer cell lines.
Tumour Biol. 36:5415–5423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liang XR, Liu YF, Chen F, Zhou ZX, Zhang
LJ and Lin ZJ: Cell Cycle-Related lncRNAs as innovative targets to
advance cancer management. Cancer Manag Res. 15:547–561. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xiao W, Wang J, Wang X, Cai S, Guo Y, Ye
L, Li D, Hu A, Jin S, Yuan B, et al: Therapeutic targeting of the
USP2-E2F4 axis inhibits autophagic machinery essential for zinc
homeostasis in cancer progression. Autophagy. 18:2615–2635. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhu M, Wang H, Ding Y, Yang Y, Xu Z, Shi L
and Zhang N: Ribonucleotide reductase holoenzyme inhibitor COH29
interacts with deubiquitinase ubiquitin-specific protease 2 and
downregulates its substrate protein cyclin D1. FASEB J.
36:e223292022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shan J, Zhao W and Gu W: Suppression of
cancer cell growth by promoting cyclin D1 degradation. Mol Cell.
36:469–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Magiera K, Tomala M, Kubica K, De Cesare
V, Trost M, Zieba BJ, Kachamakova-Trojanowska N, Les M, Dubin G,
Holak TA and Skalniak L: Lithocholic acid hydroxyamide destabilizes
cyclin D1 and Induces G (0)/G (1) arrest by inhibiting
deubiquitinase USP2a. Cell Chem Biol. 24:458–470. e182017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Nepal S, Shrestha A and Park PH: Ubiquitin
specific protease 2 acts as a key modulator for the regulation of
cell cycle by adiponectin and leptin in cancer cells. Mol Cell
Endocrinol. 412:44–55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tomala MD, Magiera-Mularz K, Kubica K,
Krzanik S, Zieba B, Musielak B, Pustula M, Popowicz GM, Sattler M,
Dubin G, et al: Identification of small-molecule inhibitors of
USP2a. Eur J Med Chem. 150:261–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kim J, Kim WJ, Liu Z, Loda M and Freeman
MR: The ubiquitin-specific protease USP2a enhances tumor
progression by targeting cyclin A1 in bladder cancer. Cell Cycle.
11:1123–1130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gabay M, Li Y and Felsher DW: MYC
activation is a hallmark of cancer initiation and maintenance. Cold
Spring Harb Perspect Med. 4:a0142412014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, Metabolism, and Cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu CH, van Riggelen J, Yetil A, Fan AC,
Bachireddy P and Felsher DW: Cellular senescence is an important
mechanism of tumor regression upon c-Myc inactivation. Proc Natl
Acad Sci USA. 104:13028–13033. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhuang D, Mannava S, Grachtchouk V, Tang
WH, Patil S, Wawrzyniak JA, Berman AE, Giordano TJ, Prochownik EV,
Soengas MS and Nikiforov MA: C-MYC overexpression is required for
continuous suppression of oncogene-induced senescence in melanoma
cells. Oncogene. 27:6623–6634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Li B, Zhang G, Wang Z, Yang Y, Wang C,
Fang D, Liu K, Wang F and Mei Y: c-Myc-activated USP2-AS1
suppresses senescence and promotes tumor progression via
stabilization of E2F1 mRNA. Cell Death Dis. 12:10062021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Iemura K, Natsume T, Maehara K, Kanemaki
MT and Tanaka K: Chromosome oscillation promotes Aurora A-dependent
Hec1 phosphorylation and mitotic fidelity. J Cell Biol.
220:e2020061162021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li P, Chen T, Kuang P, Liu F, Li Z, Liu F,
Wang Y, Zhang W and Cai X: Aurora-A/FOXO3A/SKP2 axis promotes tumor
progression in clear cell renal cell carcinoma and dual-targeting
Aurora-A/SKP2 shows synthetic lethality. Cell Death Dis.
13:6062022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shi Y, Solomon LR, Pereda-Lopez A, Giranda
VL, Luo Y, Johnson EF, Shoemaker AR, Leverson J and Liu X:
Ubiquitin-specific cysteine protease 2a (USP2a) regulates the
stability of Aurora-A. J Biol Chem. 286:38960–38968. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gu Y, Zhang Z, Camps MGM, Ossendorp F,
Wijdeven RH and Ten Dijke P: Genome-wide CRISPR screens define
determinants of epithelial-mesenchymal transition mediated immune
evasion by pancreatic cancer cells. Sci Adv. 9:eadf99152023.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen J, Ding ZY, Li S, Liu S, Xiao C, Li
Z, Zhang BX, Chen XP and Yang X: Targeting transforming growth
factor-β signaling for enhanced cancer chemotherapy. Theranostics.
11:1345–1363. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
He Q, Cao H, Zhao Y, Chen P, Wang N, Li W,
Cui R, Hou P, Zhang X and Ji M: Dipeptidyl Peptidase-4 Stabilizes
Integrin alpha4β1 complex to promote thyroid cancer cell metastasis
by activating transforming growth factor-beta signaling pathway.
Thyroid. 32:1411–1422. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tuersuntuoheti A, Li Q, Teng Y, Li X,
Huang R, Lu Y, Li K, Liang J, Miao S, Wu W and Song W: YWK-II/APLP2
inhibits TGF-β signaling by interfering with the TGFBR2-Hsp90
interaction. Biochim Biophys Acta Mol Cell Res. Jul 19–2023.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Miyazawa K and Miyazono K: Regulation of
TGF-β family signaling by inhibitory smads. Cold Spring Harb
Perspect Biol. 9:a0220952017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhao Y, Wang X, Wang Q, Deng Y, Li K,
Zhang M, Zhang Q, Zhou J, Wang HY, Bai P, et al: USP2a supports
metastasis by tuning TGF-β signaling. Cell Rep. 22:2442–2454. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Blenman KRM, Marczyk M, Karn T, Qing T, Li
X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, et al:
Predictive markers of response to neoadjuvant durvalumab with
nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in
basal-like triple-negative breast cancer. Clin Cancer Res.
28:2587–2597. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Cui Y, Zhao M, Yang Y, Xu R, Tong L, Liang
J, Zhang X, Sun Y and Fan Y: Reversal of epithelial-mesenchymal
transition and inhibition of tumor stemness of breast cancer cells
through advanced combined chemotherapy. Acta Biomater. 152:380–392.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ahangari F, Becker C, Foster DG,
Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead
B, et al: Saracatinib, a selective src kinase inhibitor, blocks
fibrotic responses in preclinical models of pulmonary fibrosis. Am
J Respir Crit Care Med. 206:1463–1479. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
van der Wal T and van Amerongen R: Walking
the tight wire between cell adhesion and WNT signalling: A
balancing act for beta-catenin. Open Biol. 10:2002672020.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kim J, Alavi Naini F, Sun Y and Ma L:
Ubiquitin-specific peptidase 2a (USP2a) deubiquitinates and
stabilizes β-catenin. Am J Cancer Res. 8:1823–1836, eCollection
2018. 2018.PubMed/NCBI
|
|
85
|
Pichiorri F, Suh SS, Rocci A, De Luca L,
Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder
H, et al: Retraction notice to: Downregulation of p53-inducible
microRNAs 192, 194, and 215 Impairs the p53/MDM2 autoregulatory
loop in multiple myeloma development. Cancer Cell. 40:14412022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wu B and Ellisen LW: Loss of p53 and
genetic evolution in pancreatic cancer: Ordered chaos after the
guardian is gone. Cancer Cell. 40:1276–1278. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hassin O and Oren M: Drugging p53 in
cancer: One protein, many targets. Nat Rev Drug Discov. 22:127–144.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Dobbelstein M and Levine AJ: Mdm2: Open
questions. Cancer Sci. 111:2203–2211. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Stevenson LF, Sparks A, Allende-Vega N,
Xirodimas DP, Lane DP and Saville MK: The deubiquitinating enzyme
USP2a regulates the p53 pathway by targeting Mdm2. EMBO J.
26:976–986. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wei T, Biskup E, Gjerdrum LM, Niazi O,
Odum N and Gniadecki R: Ubiquitin-specific protease 2 decreases
p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget.
7:48391–48400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang CL, Wang JY, Liu ZY, Ma XM, Wang XW,
Jin H, Zhang XP, Fu D, Hou LJ and Lu YC: Ubiquitin-specific
protease 2a stabilizes MDM4 and facilitates the p53-mediated
intrinsic apoptotic pathway in glioblastoma. Carcinogenesis.
35:1500–1509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shrestha M and Park PH: p53 signaling is
involved in leptin-induced growth of hepatic and breast cancer
cells. Korean J Physiol Pharmacol. 20:487–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chen W, Shi K, Liu J, Yang P, Han R, Pan
M, Yuan L, Fang C, Yu Y and Qian Z: Sustained co-delivery of
5-fluorouracil and cis-platinum via biodegradable thermo-sensitive
hydrogel for intraoperative synergistic combination chemotherapy of
gastric cancer. Bioact Mater. 23:1–15. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wang J, Zhang Y, Zhang G, Xiang L, Pang H,
Xiong K, Lu Y, Li J, Dai J, Lin S and Fu S: Radiotherapy-induced
enrichment of EGF-modified doxorubicin nanoparticles enhances the
therapeutic outcome of lung cancer. Drug Deliv. 29:588–599. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Smith ER, Wang JQ, Yang DH and Xu XX:
Paclitaxel resistance related to nuclear envelope structural
sturdiness. Drug Resist Updat. 65:1008812022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Jang JH, Lee TJ, Sung EG, Song IH and Kim
JY: Dapagliflozin induces apoptosis by downregulating
cFILPL and increasing cFILPS instability in
Caki-1 cells. Oncol Lett. 24:4012022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Poukkula M, Kaunisto A, Hietakangas V,
Denessiouk K, Katajamaki T, Johnson MS, Sistonen L and Eriksson JE:
Rapid turnover of c-FLIPshort is determined by its unique
C-terminal tail. J Biol Chem. 280:27345–27355. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Liu D, Fan Y, Li J, Cheng B, Lin W, Li X,
Du J and Ling C: Inhibition of cFLIP overcomes acquired resistance
to sorafenib via reducing ER stress-related autophagy in
hepatocellular carcinoma. Oncol Rep. 40:2206–2214. 2018.PubMed/NCBI
|
|
99
|
Iyer AK, Azad N, Talbot S, Stehlik C, Lu
B, Wang L and Rojanasakul Y: Antioxidant c-FLIP inhibits Fas
ligand-induced NF-kappaB activation in a phosphatidylinositol
3-kinase/Akt-dependent manner. J Immunol. 187:3256–3266. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Quintavalle C, Incoronato M, Puca L,
Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM and
Condorelli G: c-FLIPL enhances anti-apoptotic Akt functions by
modulation of Gsk3β activity. Cell Death Differ. 24:11342017.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Xiao Z, Liu Y, Li Q, Liu Q, Liu Y, Luo Y
and Wei S: EVs delivery of miR-1915-3p improves the
chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Cancer Chemother Pharmacol. 88:1021–1031. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
He J, Lee HJ, Saha S, Ruan D, Guo H and
Chan CH: Inhibition of USP2 eliminates cancer stem cells and
enhances TNBC responsiveness to chemotherapy. Cell Death Dis.
10:2852019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Min HY and Lee HY: Molecular targeted
therapy for anticancer treatment. Exp Mol Med. 54:1670–1694. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Assoun S, Lemiale V and Azoulay E:
Molecular targeted therapy-related life-threatening toxicity in
patients with malignancies. A systematic review of published cases.
Intensive Care Med. 45:988–997. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rosenberg T, Yeo KK, Mauguen A,
Alexandrescu S, Prabhu SP, Tsai JW, Malinowski S, Joshirao M,
Parikh K, Farouk Sait S, et al: Upfront molecular targeted therapy
for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro
Oncol. 24:1964–1975. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Harakandi C, Nininahazwe L, Xu H, Liu B,
He C, Zheng YC and Zhang H: Recent advances on the intervention
sites targeting USP7-MDM2-p53 in cancer therapy. Bioorg Chem.
116:1052732021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang YT, Cheng AC, Tang HC, Huang GC, Cai
L, Lin TH, Wu KJ, Tseng PH, Wang GG and Chen WY: USP7 facilitates
SMAD3 autoregulation to repress cancer progression in p53-deficient
lung cancer. Cell Death Dis. 12:8802021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Park SH, Fong KW, Kim J, Wang F, Lu X, Lee
Y, Brea LT, Wadosky K, Guo C, Abdulkadir SA, et al:
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7
deubiquitin complex in prostate cancer. Sci Adv. 7:eabe22612021.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Su D, Wang W, Hou Y, Wang L, Yi X, Cao C,
Wang Y, Gao H, Wang Y, Yang C, et al: Bimodal regulation of the
PRC2 complex by USP7 underlies tumorigenesis. Nucleic Acids Res.
49:4421–4440. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang L, Wang H, Tian L and Li H:
Expression of USP7 and MARCH7 is correlated with poor prognosis in
epithelial ovarian cancer. Tohoku J Exp Med. 239:165–175. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu M, Zhang Y, Wu Y, Jin J, Cao Y, Fang
Z, Geng L, Yang L, Yu M, Bu Z, et al: IKZF1 selectively enhances
homologous recombination repair by interacting with CtIP and USP7
in multiple myeloma. Int J Biol Sci. 18:2515–2526. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhu Y, Gu L, Lin X, Cui K, Liu C, Lu B,
Zhou F, Zhao Q, Shen H and Li Y: LINC00265 promotes colorectal
tumorigenesis via ZMIZ2 and USP7-mediated stabilization of
β-catenin. Cell Death Differ. 27:1316–1327. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Ullah S, Junaid M, Liu Y, Chen S, Zhao Y
and Wadood A: Validation of catalytic site residues of Ubiquitin
Specific Protease 2 (USP2) by molecular dynamic simulation and
novel kinetics assay for rational drug design. Mol Divers.
27:1323–1332. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Metzig M, Nickles D, Falschlehner C,
Lehmann-Koch J, Straub BK, Roth W and Boutros M: An RNAi screen
identifies USP2 as a factor required for TNF-α-induced NF-κB
signaling. Int J Cancer. 129:607–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang
Q, Lin Y, Li J, Kang T, Tao M, et al: Disrupting the interaction of
BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like
breast cancer. Cancer Cell. 25:210–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Peinado H and Cano A: A hypoxic twist in
metastasis. Nat Cell Biol. 10:253–254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mladinich M, Ruan D and Chan CH: Tackling
cancer stem cells via inhibition of EMT transcription factors. Stem
Cells Int. 2016:52858922016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kim JY, Cho TM, Park JM, Park S, Park M,
Nam KD, Ko D, Seo J, Kim S, Jung E, et al: A novel HSP90 inhibitor
SL-145 suppresses metastatic triple-negative breast cancer without
triggering the heat shock response. Oncogene. 41:3289–3297. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Shih YY, Lin HY, Jan HM, Chen YJ, Ong LL,
Yu AL and Lin CH: S-glutathionylation of Hsp90 enhances its
degradation and correlates with favorable prognosis of breast
cancer. Redox Biol. 57:1025012022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Leow CC, Chesebrough J, Coffman KT,
Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B and
Chang Y: Antitumor efficacy of IPI-504, a selective heat shock
protein 90 inhibitor against human epidermal growth factor receptor
2-positive human xenograft models as a single agent and in
combination with trastuzumab or lapatinib. Mol Cancer Ther.
8:2131–2141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Workman P, Burrows F, Neckers L and Rosen
N: Drugging the cancer chaperone HSP90: Combinatorial therapeutic
exploitation of oncogene addiction and tumor stress. Ann N Y Acad
Sci. 1113:202–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Modi S, Stopeck A, Linden H, Solit D,
Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME,
Sugarman S, et al: HSP90 inhibition is effective in breast cancer:
A phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Sesto N, Wurtzel O, Archambaud C, Sorek R
and Cossart P: The excludon: A new concept in bacterial antisense
RNA-mediated gene regulation. Nat Rev Microbiol. 11:75–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Qu X, Alsager S, Zhuo Y and Shan B: HOX
transcript antisense RNA (HOTAIR) in cancer. Cancer Lett.
454:90–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chen SP, Zhu GQ, Xing XX, Wan JL, Cai JL,
Du JX, Song LN, Dai Z and Zhou J: LncRNA USP2-AS1 promotes
hepatocellular carcinoma growth by enhancing YBX1-Mediated HIF1α
protein translation under hypoxia. Front Oncol. 12:8823722022.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Pirnia F, Schneider E, Betticher DC and
Borner MM: Mitomycin C induces apoptosis and caspase-8 and −9
processing through a caspase-3 and Fas-independent pathway. Cell
Death Differ. 9:905–914. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wang WD, Shang Y, Wang C, Ni J, Wang AM,
Li GJ, Su L and Chen SZ: c-FLIP promotes drug resistance in
non-small-cell lung cancer cells via upregulating FoxM1 expression.
Acta Pharmacol Sin. 43:2956–2966. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yang Y, Hou JQ, Qu LY, Wang GQ, Ju HW,
Zhao ZW, Yu ZH and Yang HJ: Differential expression of USP2, USP14
and UBE4A between ovarian serous cystadenocarcinoma and adjacent
normal tissues. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23:504–506.
2007.(In Chinese). PubMed/NCBI
|
|
130
|
Guo B, Yu L, Sun Y, Yao N and Ma L: Long
Non-Coding RNA USP2-AS1 accelerates cell proliferation and
migration in ovarian cancer by sponging miR-520d-3p and
Up-Regulating KIAA1522. Cancer Manag Res. 12:10541–10550. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li D, Bao J, Yao J and Li J: lncRNA
USP2-AS1 promotes colon cancer progression by modulating Hippo/YAP1
signaling. Am J Transl Res. 12:5670–5682, eCollection 2020.
2020.PubMed/NCBI
|
|
132
|
Tatari N, Khan S, Livingstone J, Zhai K,
McKenna D, Ignatchenko V, Chokshi C, Gwynne WD, Singh M, Revill S,
et al: The proteomic landscape of glioblastoma recurrence reveals
novel and targetable immunoregulatory drivers. Acta Neuropathol.
144:1127–1142. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ji YR, Cheng CC, Lee AL, Shieh JC, Wu HJ,
Huang AP, Hsu YH and Young TH: Poly (allylguanidine)-coated
surfaces regulate TGF-β in glioblastoma cells to induce apoptosis
via NF-κB Pathway Activation. ACS Appl Mater Interfaces.
13:59400–59410. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Joseph JV, Magaut CR, Storevik S, Geraldo
LH, Mathivet T, Latif MA, Rudewicz J, Guyon J, Gambaretti M, Haukas
F, et al: TGF-β promotes microtube formation in glioblastoma
through thrombospondin 1. Neuro Oncol. 24:541–553. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Yan X, Liao H, Cheng M, Shi X, Lin X, Feng
XH and Chen YG: Smad7 protein interacts with receptor-regulated
smads (R-Smads) to inhibit transforming growth factor-β
(TGF-β)/smad signaling. J Biol Chem. 291:382–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Girish V, Lakhani AA, Thompson SL, Scaduto
CM, Brown LM, Hagenson RA, Sausville EL, Mendelson BE, Kandikuppa
PK, Lukow DA, et al: Oncogene-like addiction to aneuploidy in human
cancers. Science. Jul 6–2023.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Mejia-Hernandez JO, Raghu D, Caramia F,
Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG,
Abrahmsén L, Blandino G, et al: Targeting MDM4 as a novel
therapeutic approach in prostate cancer independent of p53 status.
Cancers (Basel). 14:39472022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Tsai KW, Kuo WT and Jeng SY: Tight
junction protein 1 dysfunction contributes to cell motility in
bladder cancer. Anticancer Res. 38:4607–4615. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Chuang SJ, Cheng SC, Tang HC, Sun CY and
Chou CY: 6-Thioguanine is a noncompetitive and slow binding
inhibitor of human deubiquitinating protease USP2. Sci Rep.
8:31022018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Renatus M, Parrado SG, D'Arcy A, Eidhoff
U, Gerhartz B, Hassiepen U, Pierrat B, Riedl R, Vinzenz D,
Worpenberg S and Kroemer M: Structural basis of ubiquitin
recognition by the deubiquitinating protease USP2. Structure.
14:1293–1302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kitamura H and Hashimoto M: USP2-Related
cellular signaling and consequent pathophysiological outcomes. Int
J Mol Sci. 22:12092021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Graner E, Tang D, Rossi S, Baron A, Migita
T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti
S and Loda M: The isopeptidase USP2a regulates the stability of
fatty acid synthase in prostate cancer. Cancer Cell. 5:253–261.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Cheng JC, Bai A, Beckham TH, Marrison ST,
Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, et al:
Radiation-induced acid ceramidase confers prostate cancer
resistance and tumor relapse. J Clin Invest. 123:4344–4358. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Mizutani N, Inoue M, Omori Y, Ito H,
Tamiya-Koizumi K, Takagi A, Kojima T, Nakamura M, Iwaki S,
Nakatochi M, et al: Increased acid ceramidase expression depends on
upregulation of androgen-dependent deubiquitinases, USP2, in a
human prostate cancer cell line, LNCaP. J Biochem. 158:309–319.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Vieyra-Garcia PA and Wolf P: A deep dive
into UV-based phototherapy: Mechanisms of action and emerging
molecular targets in inflammation and cancer. Pharmacol Ther.
222:1077842021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Nakahashi K, Nihira K, Suzuki M, Ishii T,
Masuda K and Mori K: A novel mouse model of cutaneous T-cell
lymphoma revealed the combined effect of mogamulizumab with
psoralen and ultraviolet a therapy. Exp Dermatol. 31:1693–1698.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Hsu J and Sage J: Novel functions for the
transcription factor E2F4 in development and disease. Cell Cycle.
15:3183–3190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Moghadami AA, Aboutalebi Vand Beilankouhi
E, Kalantary-Charvadeh A, Hamzavi M, Mosayyebi B, Sedghi H,
Ghorbani Haghjo A and Nazari Soltan Ahmad S: Inhibition of USP14
induces ER stress-mediated autophagy without apoptosis in lung
cancer cell line A549. Cell Stress Chaperones. 25:909–917. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Liu C, Chen Z, Ding X, Qiao Y and Li B:
Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced
apoptosis by stabilizing BIRC3 in non-small cell lung cancer. Lab
Invest. 102:524–533. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Chen J, Dexheimer TS, Ai Y, Liang Q,
Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A and Zhuang
Z: Selective and cell-active inhibitors of the USP1/UAF1
deubiquitinase complex reverse cisplatin resistance in non-small
cell lung cancer cells. Chem Biol. 18:1390–1400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu
B and Huang J: Knockdown of ubiquitin-specific protease 51
attenuates cisplatin resistance in lung cancer through
ubiquitination of zinc-finger E-box binding homeobox 1. Mol Med
Rep. 22:1382–1390. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zhang L, Xu B, Qiang Y, Huang H, Wang C,
Li D and Qian J: Overexpression of deubiquitinating enzyme USP28
promoted non-small cell lung cancer growth. J Cell Mol Med.
19:799–805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Zhang Z, Cui Z, Xie Z, Li C, Xu C, Guo X,
Yu J, Chen T, Facchinetti F, Bohnenberger H, et al: Deubiquitinase
USP5 promotes non-small cell lung cancer cell proliferation by
stabilizing cyclin D1. Transl Lung Cancer Res. 10:3995–4011. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Zhu M, Zhang H, Lu F, Wang Z, Wu Y, Chen
H, Fan X, Yin Z and Liang F: USP52 inhibits cell proliferation by
stabilizing PTEN protein in non-small cell lung cancer. Biosci Rep.
41:BSR202104862021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Zhang F, Zhao Y and Sun Y: USP2 is an SKP2
deubiquitylase that stabilizes both SKP2 and its substrates. J Biol
Chem. 297:1011092021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Zhou J, Wang T, Qiu T, Chen Z, Ma X, Zhang
L and Zou J: Ubiquitin-specific protease-44 inhibits the
proliferation and migration of cells via inhibition of JNK pathway
in clear cell renal cell carcinoma. BMC Cancer. 20:2142020.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Hu W, Su Y, Fei X, Wang X, Zhang G, Su C,
Du T, Yang T, Wang G, Tang Z and Zhang J: Ubiquitin specific
peptidase 19 is a prognostic biomarker and affect the proliferation
and migration of clear cell renal cell carcinoma. Oncol Rep.
43:1964–1974. 2020.PubMed/NCBI
|
|
158
|
Meng X, Xiong Z, Xiao W, Yuan C, Wang C,
Huang Y, Tong J, Shi J, Chen Z, Liu C, et al: Downregulation of
ubiquitin-specific protease 2 possesses prognostic and diagnostic
value and promotes the clear cell renal cell carcinoma progression.
Ann Transl Med. 8:3192020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yi J, Tavana O, Li H, Wang D, Baer RJ and
Gu W: Targeting USP2 regulation of VPRBP-mediated degradation of
p53 and PD-L1 for cancer therapy. Nat Commun. 14:19412023.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhu L, Chen Z, Guo T, Chen W, Zhao L, Guo
L and Pan X: USP2 inhibits lung cancer pathogenesis by reducing
ARID2 protein degradation via ubiquitination. Biomed Res Int.
2022:15252162022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Estlin EJ: Continuing therapy for
childhood acute lymphoblastic leukaemia: Clinical and cellular
pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Cancer Treat Rev. 27:351–363. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Vora A, Mitchell CD, Lennard L, Eden TO,
Kinsey SE, Lilleyman J and Richards SM; Medical Research Council;
National Cancer Research Network Childhood Leukaemia Working Party,
: Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in
childhood lymphoblastic leukaemia: A randomised trial. Lancet.
368:1339–1348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Lin HC, Kuan Y, Chu HF, Cheng SC, Pan HC,
Chen WY, Sun CY and Lin TH: Disulfiram and 6-Thioguanine
synergistically inhibit the enzymatic activities of USP2 and USP21.
Int J Biol Macromol. 176:490–497. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Tsai HK, Gibson CJ, Murdock HM, Davineni
P, Harris MH, Wang ES, Gondek LP, Kim AS, Nardi V and Lindsley RC:
Allelic complexity of KMT2A partial tandem duplications in acute
myeloid leukemia and myelodysplastic syndromes. Blood Adv.
6:4236–4240. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhou X, Zhang P, Aryal S, Zhang L and Lu
R: UTX loss alters therapeutic responses in KMT2A-rearranged acute
myeloid leukemia. Leukemia. 37:226–230. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ikeda J, Shiba N, Tsujimoto SI, Yoshida M,
Nakabayashi K, Ogata-Kawata H, Okamura K, Takeuchi M, Osumi T,
Tomizawa D, et al: Whole transcriptome sequencing reveals a
KMT2A-USP2 fusion in infant acute myeloid leukemia. Genes
Chromosomes Cancer. 58:669–672. 2019.PubMed/NCBI
|
|
167
|
Lopes BA, Poubel CP, Teixeira CE,
Caye-Eude A, Cave H, Meyer C, Marschalek R, Boroni M and
Emerenciano M: Novel Diagnostic and therapeutic options for
KMT2A-Rearranged acute leukemias. Front Pharmacol. 13:7494722022.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Blackburn PR, Smadbeck JB, Znoyko I,
Webley MR, Pitel BA, Vasmatzis G, Xu X, Greipp PT, Hoppman NL,
Ketterling RP, et al: Cryptic and atypical KMT2A-USP2 and
KMT2A-USP8 rearrangements identified by mate pair sequencing in
infant and childhood leukemia. Genes Chromosomes Cancer.
59:422–427. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Meyer C, Lopes BA, Caye-Eude A, Cave H,
Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, et al:
Human MLL/KMT2A gene exhibits a second breakpoint cluster region
for recurrent MLL-USP2 fusions. Leukemia. 33:2306–2340. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Liu J, Cheng Y, Zheng M, Yuan B, Wang Z,
Li X, Yin J, Ye M and Song Y: Targeting the
ubiquitination/deubiquitination process to regulate immune
checkpoint pathways. Signal Transduct Target Ther. 6:282021.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Savage RE, Tyler AN, Miao XS and Chan TC:
Identification of a novel glucosylsulfate conjugate as a metabolite
of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ
501, beta-lapachone) in mammals. Drug Metab Dispos. 36:753–758.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ohayon S, Refua M, Hendler A, Aharoni A
and Brik A: Harnessing the oxidation susceptibility of
deubiquitinases for inhibition with small molecules. Angew Chem Int
Ed Engl. 54:599–603. 2015.PubMed/NCBI
|
|
173
|
Nguyen TT, Ung TT, Li S, Sah DK, Park SY,
Lian S and Jung YD: Lithocholic Acid Induces miR21, Promoting PTEN
Inhibition via STAT3 and ERK-1/2 signaling in colorectal cancer
cells. Int J Mol Sci. 22:102092021. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Li W, Wang Z, Lin R, Huang S, Miao H, Zou
L, Liu K, Cui X, Wang Z, Zhang Y, et al: Lithocholic acid inhibits
gallbladder cancer proliferation through interfering
glutaminase-mediated glutamine metabolism. Biochem Pharmacol.
205:1152532022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Altun M, Kramer HB, Willems LI, McDermott
JL, Leach CA, Goldenberg SJ, Kumar KG, Konietzny R, Fischer R,
Kogan E, et al: Activity-based chemical proteomics accelerates
inhibitor development for deubiquitylating enzymes. Chem Biol.
18:1401–1412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis,
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Yang H, Landis-Piwowar KR, Chen D, Milacic
V and Dou QP: Natural compounds with proteasome inhibitory activity
for cancer prevention and treatment. Curr Protein Pept Sci.
9:227–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Issaenko OA and Amerik AY: Chalcone-based
small-molecule inhibitors attenuate malignant phenotype via
targeting deubiquitinating enzymes. Cell Cycle. 11:1804–1817. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Aleo E, Henderson CJ, Fontanini A, Solazzo
B and Brancolini C: Identification of new compounds that trigger
apoptosome-independent caspase activation and apoptosis. Cancer
Res. 66:9235–9244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Nicholson B, Leach CA, Goldenberg SJ,
Francis DM, Kodrasov MP, Tian X, Shanks J, Sterner DE, Bernal A,
Mattern MR, et al: Characterization of ubiquitin and
ubiquitin-like-protein isopeptidase activities. Protein Sci.
17:1035–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Vamisetti GB, Meledin R, Gopinath P and
Brik A: Halogen Substituents in the Isoquinoline Scaffold Switches
the Selectivity of Inhibition between USP2 and USP7. Chembiochem.
20:282–286. 2019.PubMed/NCBI
|
